Evidence map›Paper›PMID 25143959›Full record

ArticleAmerican journal of clinical and experimental urology2014

Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Noriko N Yokoyama, Shujuan Shao, Bang H Hoang, Dan Mercola, Xiaolin Zi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.International journal of radiation oncology, biology, physics · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. SOX4: The unappreciated oncogene.Seminars in cancer biology · 2020
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Noriko N YokoyamaDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Shujuan ShaoDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Bang H HoangDepartment of Pharmaceutical Sciences, University of California, Irvine, Orange, CA 92868, USA.
Dan MercolaChao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA ; Department of Othopeadic Surgery, University of California, Irvine, Orange, CA 92868, USA ; Department of Pathology and Laboratory Medicine, University of California, Irvine, Orange, CA 92868, USA.
Xiaolin ZiDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA ; Department of Pharmaceutical Sciences, University of California, Irvine, Orange, CA 92868, USA ; Department of Pharmacology, University of California, Irvine, Orange, CA 92868, USA ; Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA.
University of California, Irvine · US

Funding

Chemoprevention of urinary bladder carcinogenesis by flavokawain AR01CA122558 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2008 to 2012
$1.7M
Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate CancerR21CA166839 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LILLY, MICHAEL B, ZI, XIAOLIN · 2013 to 2014
$369k
Rhodiola Rosea Extracts, Salidroside and Bladder Cancer ChemopreventionR21CA152804 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2011 to 2012
$366k
NCI NIH HHS R01 CA122558NCI NIH HHS R21 CA152804NCI NIH HHS R21 CA166839
6 · The paper itself

Abstract

Increasing evidence has indicated that Wnt signaling plays complex roles in castration resistant prostate cancer (CRPC). Although not all data were consistent, β-catenin nuclear localization and its co-localization with androgen receptor (AR) were more frequently observed in CRPC compared to hormone naïve prostate cancer. This direct interaction between AR and β-catenin seemed to elicit a specific expression of a set of target genes in low androgen conditions in CRPC. Paracrine Wnt signaling also was shown to aid resistance to chemotherapy and androgen deprivation therapy. Results from the next generation sequencing studies (i.e. RNA-seq and whole exosome sequcing) of CRPC specimens have identified the Wnt pathway as one of the top signaling pathways with significant genomic alterations in CRPC, whereas, Wnt pathway alterations were virtually absent in hormone naïve primary prostate cancer. Furthermore, Wnt signaling has been suggested to play an important role in cancer stem cell functions in prostate cancer recurrence and resistance to androgen deprivation therapy. Therefore, in this review we have summarized existing knowledge regarding potential roles of Wnt signaling in CRPC and underline Wnt signaling as a potential therapeutic target for CRPC. Further understanding of Wnt signaling in castration resistance may eventually contribute new insights into possible treatment options for this incurable disease.

Indexed as

castration-resistant prostate cancertargeted therapyWnt signaling

Identifiers

PMID25143959
PMCPMC4219296
OpenAlexW2270095349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.